Open main menu

Psychiatrienet β

Combining-Topiramate-Gabapentin

Revision as of 00:12, 10 March 2010 by Klaas (talk | contribs) (Created page with '{{Drugcombi | base = topiramate | add = gabapentin | info = * Topiramate induces CYP3A4 and is an inhibiter of CYP2C19. * Gabapentine is eliminated unchanged by the kidney for ...')
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Topiramate
Type moodstabilizer
Group anticonvulsant
links
ATC-code N03AX11
PubChem 5284627
PubMed Topiramate
Drugs.com topiramate
Kompas (Dutch) Topiramate
Wikipedia Topiramate
Gabapentin
Type moodstabilizer
Group anticonvulsant
links
ATC-code N03AX12
PubChem 3446
PubMed Gabapentin
Drugs.com gabapentin
Kompas (Dutch) Gabapentin
Wikipedia Gabapentin

Adding gabapentin to topiramate.

Infobord.png General information
  • Topiramate induces CYP3A4 and is an inhibitor of CYP2C19.
  • Gabapentin is eliminated unchanged by the kidney for 100%.
  • Topiramate induces CYP3A4 and is an inhibiter of CYP2C19.
  • Gabapentine is eliminated unchanged by the kidney for 100%. Changes in the rate of excretion can cause unwanted effects.
  • This combination of drugs may have possible synergistic effects. There are no reports for pharmacokinetic drug interactions. However, the combination will have additional side effects.
Eenrichtingbord.png Start gabapentin
  • Start topiramate according to the general dosing advice.



  1. 1.0 1.1 1.2 Farmacotherapeutisch Kompas - topiramaat (dutch) Cite error: Invalid <ref> tag; name "ftk" defined multiple times with different content
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.